Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > looks to me

<< Previous

Bullboard Posts

Next >>

Comment by Doccoleon Apr 19, 2021 5:06pm

162 Views

Post# 33024153

RE:RE:RE:RE:RE:RE:RE:RE:looks to me

You didn't miss much. He went through the deck and answered some outstanding questions.

waiting on the integration,
waiting on end of phase 2,
waiting on start of phase 3, waiting waiting....and that's why this stock is where it's at!

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing